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Abstract
Background: In recent years, efforts have been made to improve paediatric drug therapy. The aim of this research was to
investigate any changes regarding the frequency and nature of adverse drug reactions (ADRs) in hospitalized children in
one paediatric general medical ward over a 9-year period.
Methodology: Two prospective observational cohort studies were conducted at a large University hospital in Germany in
1999 and 2008, respectively. Children aged 0–18 years admitted to the study ward during the study periods were included.
ADRs were identified using intensive chart review. Uni- and multivariable regression has been used for data analysis.
Results: A total of 520 patients (574 admissions) were included [1999: n = 144 (167); 2008: n = 376 (407)]. Patients received a
total of 2053 drugs [median 3, interquartile range (IQR) 2–5]. 19% of patients did not receive any medication. Median length
of stay was 4 days (IQR 3–7; range 1–190 days) with a significantly longer length of stay in 1999. The overall ADR incidence
was 13.1% (95% CI, 9.8–16.3) varying significantly between the two study cohorts [1999: 21.9%, 95% CI, 14.7–29.0; 2008:
9.2%, 95% CI, 5.9–12.5 (p,0.001)]. Antibacterials and corticosteroids for systemic use caused most of the ADRs in both
cohorts (1999; 2008). Exposure to systemic antibacterials decreased from 62.9% to 43.5% whereas exposure to analgesics
and anti-inflammatory drugs increased from 17.4% to 45.2%, respectively. The use of high risk drugs decreased from 75% to
62.2%. In 1999, 45.7% and in 2008 96.2% of ADRs were identified by treating clinicians (p,0.001).
Conclusions: Between 1999 and 2008, the incidence of ADRs decreased significantly. Improved treatment strategies and an
increased awareness of ADRs by physicians are most likely to be the cause for this positive development. Nevertheless
further research on ADRs particularly in primary care and the establishment of prospective pharmacovigilance systems are
still needed.
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Introduction
Over the last ten years the needs of children receiving
pharmacotherapy have been increasingly recognized. Legislation
was introduced in both the US [1] and, more recently, the EU [2]
to facilitate the conduct of clinical trials in the paediatric
population. Furthermore, funding was made available to establish
paediatric networks and to increase research capacities [3].
Pharmacovigilance plays an important role in drug develop-
ment and, because of the difficulties in conducting clinical trials, it
is even more important in the paediatric population.
Investigating the frequency and nature of ADRs in children and
adolescents is one important aspect of pharmacovigilance. Within
the last few years various observational studies and meta-analyses
were conducted to establish the epidemiology of ADRs in
hospitalised children [4–11].
It has been shown that the incidence of ADRs in hospitalized
children is about 10% [5,6,8,12]. A large systematic review by
Smyth et al indicated that the incidence rate for ADRs causing
hospital admission is 2.9% [11]. An analysis of population based
data revealed that about 2% of children taking medicines in the
community experience an ADR [13].
At the Department of Paediatric and Adolescent Medicine,
University Hospital Erlangen we conducted our first study
investigating ADRs in children in 1999 [14]. Almost ten years
later, in 2008 and within the set up of a larger international study
(ADVISE) we collected similar data from the same ward [15].
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ADVISE (Adverse Drug Reaction in Children – International
Surveillance and Evaluation) is a multicentre study which
investigated the incidence of ADRs in hospitalised children in
five European and non-European countries.
Between the conduct of these two studies falls the introduction
of diagnosis related groups (DRGs) for reimbursement of costs
during hospitalization in our hospital. Contrary to previous
methods this system is a case-based system, reimbursing hospitals
for the treatment of patients based on the diagnosis and the
procedures performed but independent of the length of hospital
stay [16]. A reduction of the duration of hospital treatments was
anticipated [17]. However, whether there is an impact on patients’
safety so far remains unclear.
In the present manuscript we compare the results of these two
cohort studies and investigate any changes in the frequency and
nature of ADRs at our University Children Hospital between 1999
and 2008.
Methods
Study design
Two prospective observational cohort studies were conducted at
the Department of Paediatric and Adolescents Medicine at the
University Hospital Erlangen in Germany during an 8-month
period from July 1999 to March 2000 and during a 3-month
period from October to December in 2008, respectively. The first
cohort study (Weiß et al study, 1999 cohort) was a pilot ADR-
surveillance [14], the second cohort study (German part of
ADVISE study, 2008 cohort) was part of the international
ADVISE-project [15].
Study setting
A general paediatric ward with a main focus on the treatment of
infectious diseases. Between 1999 and 2008 the number of beds
increased from 10 to 24 on this ward. Both studies were approved
by the Ethics Committee at the University Hospital Erlangen.
Study population
Inclusion criteria. All children aged 0 to 18 years admitted
to the study ward within the respective study periods.
Exclusion criteria. Children with a length of hospital stay
less than 24 hours; children with a main diagnosis of neoplasm.
Database and data collection
Data collected in both cohort studies included: patient
demographics (age, gender), medication data (dosage, route of
administration, frequency, start and end date of each prescription)
and admission diagnosis. For prescribed drugs each chemical
compound or combination compound according to the Anatomic
Therapeutic Chemical (ATC) classification was considered only
once per patient [18]. Fluid and electrolyte infusions and
parenteral nutrition were excluded.
Data were collected in a standardized format. For standardi-
zation the established international terminologies of ATC [18] for
medication, International Classification of Diseases version 10
(ICD10 [19]) for diagnosis and WHO Adverse Reaction
Terminology (WHO-ART) [20] ) for adverse drug reactions were
used.
Data from the 1999 cohort (Weiß et al study) were coded
retrospectively for the purpose of this study and restricted to
patients less than 18 years old. For the 2008 cohort (German part
of ADVISE study) standardization was achieved through an online
database application designed specifically for the ADVISE project
(www.paediatric-adr.com).
Adverse drug reactions (ADRs) identification
Adverse drug reactions were identified by intensive chart
review, which is recognized as the gold standard for obtaining
data on the incidence of ADRs [14,21]. One researcher in each
team screened all patient records regularly for events that could
potentially be related to medication. This also included events
which were present at admission and thus were potential ADRs
leading to admission. All potential ADRs were then presented to
the research team that reviewed the patient record including
laboratory data and assessed whether the event was an ADR as
defined by the WHO [22]. Each member of the team made his/
her individual judgement and a final decision was made by
consensus after discussion in the group. In both studies, ward staff
was encouraged to monitor patients regarding ADRs.
Assessment of ADRs
All ADRs were assessed using established algorithms. The
causality/probability of ADRs was estimated using the Naranjo
score [23] while severity was assessed using a weighted score
published by Dormann et al. (2000) [24]. In regard to the
preventability of an ADR the algorithm by Schumock and
Thornton (1992) [25] was used. For each ADR the time of
occurrence was documented as follows: , ‘‘before admission’’,
‘‘before admission and reason for admission’’ and ‘‘during
admission’’.
High risk drugs
Based on drug groups being described as most frequently
involved in the occurrence of ADRs in the literature [26–30] and
the opinions of two paediatric clinical pharmacologists involved in
the project (W.R., N.C.) we defined five drug groups (ATC
therapeutic level) as high risk: these were analgesics (N02),
antiepileptics (N03), antibacterials and antimycotics for systemic
use (J01, J02), corticosteroids for systemic use (H02), and
immunosuppressant agents (L04) [31].
Other drugs were grouped as low risk drugs.
Physicians’ awareness
Physicians’ awareness towards ADRs was also monitored. If
relevant chart notes, changes in drug regimen, additional
laboratory tests or other diagnostic measures were found in the
patient’s chart, the ADR was assumed to be ‘‘recognised’’. If no
evidence was found in the patient record that the responsible
physician recognised the ADR, it was categorised as ‘‘not
recognised’’. Physicians’ awareness was defined as the number of
ADRs recognised by ward physicians divided by the total number
of ADR.
Statistical Analysis
Statistical analysis was performed using PASW Statistics 18 and
Stata 11. Chi-squared-test was used to compare the proportions.
In all statistical tests differences were considered to be significant at
a p-value of ,0.05.
Further analysis for possible risk factors that contribute to the
occurrence of ADRs in each study cohort was conducted using
univariable and multivariable regression methods. These analyses
were conducted at patient level and ADR occurrence was used as
the outcome measure. Initial association between individual
variables and the incidence of ADRs was examined using a Chi-
squared test. Univariable regression analysis was run for those
variables which showed significance in the Chi-squared test. The
multivariable logistic regression model included all variables that
showed significant association in the univariable analysis. The full
ADRs Children Germany
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regression model was adjusted by length of stay and possible
confounding factors (age, gender, numbers of low risk drugs and
high risk drugs prescribed and diseases).
Exposure rates
Overall exposure rates were defined as the number of patients
receiving at least one prescription of a drug class divided by the
total number of admissions during the study period. In addition we
also calculated exposure rates for patients receiving at least one
medication during their hospital stay. We calculated the exposure
rates for analgesics, anti-inflammatory drugs and for antiinfectives
for systemic use, because these were the most frequently prescribed
drugs and the drug classes with the largest differences between the
two studies.
ADR incidence
The incidence of patients with ADRs was defined as the number
of patients with an ADR divided by the number of patients
receiving medications in the cohort.
In addition, we also calculated the proportion of patients
experiencing an ADR. It was defined as the number of patients
with at least one ADR divided by the total number of patients in
the cohort and thus also including those patients not receiving any
medication.
The proportion of all admissions that resulted from a drug taken
prior to admission was calculated using the number of patients
admitted due to an ADR divided by the total number of patients in
the study cohort.
All results were multiplied by 100 and stratified by year of the
study. For the purpose of incidence/proportion calculations and
number of ADRs per patient, only the first patient admission was
considered.
In order to adjust for the differences between the two cohort
studies in observation periods and the duration of stay in hospital
we also calculated the number of ADRs per 100 admissions, and
per 100 days of hospital stay.
The total number of ADRs that occurred in the study cohort
was based on all admissions.
Results
Study population
A total of 520 children (544 admissions) were included in the
analysis [(1999 cohort): n = 144, (167); (2008 cohort): n = 376,
(407)]. 229 children (44%) were female and the median age was 4
years (IQR 1–10, range 0–18 years). The total length of hospital
stay in the whole population was 3231 days with a median of 4
days (IQR 3–7, range 0–190 days). Of the 520 hospitalised
children 421 (81%) received at least one drug during their stay. In
total 2053 drugs were prescribed to these 421 patients with a
median of 3 drugs per patient (IQR 2–5, range 1–25).
Demographic characteristics of children included from each study
are shown in table 1. The length of hospitalisation decreased
significantly from median 5 days to median 4 days (p,0.001)
There was also a significant difference between the two studies
with respect to age (p,0.05), number of diagnoses, number of
patients on medication and number of drugs prescribed per
patient (p,0.001). There was no significant difference in gender
between the two study groups (p = 0.69) (Table 1).
Diagnoses
In both studies the most common main diagnoses were
infectious and parasitic diseases followed by respiratory system
diseases.
In the 2008 cohort children with cystic fibrosis were less
common but more children were admitted for monitoring
purposes. Furthermore there was a higher number of diagnosis
of ICD-class ‘‘E= endocrine, nutritional and metabolic diseases’’.
(Figure 1) The percentage of patients with more than 3 diagnoses
was significantly higher in the 2008 cohort (17.3% vs. 5.6%,
p,0.001). (Figure 1)
Drug prescriptions
A total of 2053 prescriptions were documented in the study
population. 710 prescriptions were recorded for the 1999 cohort
and 1343 for the 2008 cohort, respectively.
In both study cohorts ‘‘antiinfectives for systemic use’’ were
prescribed most frequently. Within this group the use of the
subgroups ‘‘antibacterials for systemic use’’ (28.4% vs. 21.7%),
‘‘antimycobacterials’’ (1.7% vs. 0.1%) and ‘‘antimycotics for
systemic use’’ (0.8% vs. 0.2%) decreased between 1999 and
2008 whereas the use of ‘‘antivirals for systemic use’’ (0.1% vs.
1.6%) increased.
In the 1999 cohort, drugs for obstructive airway diseases
(10.8%) and cough and cold medicines (10.1%) were the second
most frequently prescribed, whereas in the 2008 cohort analgesics
(16.8%) and anti-inflammatory & antirheumatic drugs (8.9%) were
the second most frequently prescribed. The use of analgesics and
anti-inflammatory drugs increased significantly from 3.3% in the
1999 cohort to 25.6% of all prescriptions in the 2008 cohort,
respectively. (Figure 2)
Exposure rates
Overall exposure rates, i.e. the number of children receiving at
least one antiinfective for systemic use decreased from 62.9% to
42.5%. (Table 2) In contrast, the overall exposure rate for
analgesics and anti-inflammatory drugs increased from 17.4% to
45.2%. Amongst patients receiving at least one medication the
exposure rates changed from 82.0% to 59.0% for antiinfectives for
systemic use and from 22.7% to 62.8% for analgesics and anti-
inflammatory drugs, respectively. The drugs mostly responsible for
this increase were metamizol, paracetamol and ibuprofen, which
were almost not used at all in the 1999 cohort but prescribed to
almost one third of the patients in the 2008 cohort (paraceta-
mol = 24.6%, metamizol = 28.3%, ibuprofen = 29.2%). (Table 2)
High risk drugs
The percentage of children with at least one prescription of a
high risk drug decreased from 75% (95% CI, 67.1–81.8) to 62.2%
(95% CI, 57.1–67.2) between the two time periods. Amongst those
receiving at least one medication this percentage changed from
84.4% (95% CI, 76.9–90.2) to 79.8% (95% CI, 74.8–84.3),
respectively. In the 1999 cohort significantly more children
received more than one high risk drug (p,0.05). (Table 1)
ADR incidence
55 out of 520 patients developed a total of 99 ADRs. The
overall proportion of ADRs in the study cohort was 10.6% (95%
CI, 7.9–13.2).
ADR incidence in the 1999 cohort was 21.9% (95% CI, 14.7–
29.0) decreasing to 9.2% (95% CI, 5.9–12.5) in the 2008 cohort.
In both studies the ADR incidence was found to be higher in older
children (.11–18 years) although this association was stronger in
2008.
The proportion of patients with an ADR as a reason for
admission was 0.0% in 1999 and 0.8% in 2008 (95% CI, 20.2–
2.3) when 3 patients were hospitalised because of an ADR.
ADRs Children Germany
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(Table 3) Incidences based on other denominators are given in
table 3.
ADR characteristics
In the 1999 cohort gastrointestinal-system disorders (n = 10;
21.7%), skin & appendages disorders (n = 9; 19.6%) and
disorders of the white cells & the reticulo-endothelial system
(n = 9; 19.6%) were the most frequently documented ADRs
according to the WHO system organ classes, whereas in the
2008 cohort disorders of the white cells & the reticulo-
endothelial system (n = 16; 30.2%) followed by metabolic &
nutritional disorders (n = 10; 18.9%) and disorders of the central
or peripheral nervous system (n = 6; 11.3%) were the ADR-
classes observed most commonly.
117 drugs were suspected as a possible cause for these 99 ADRs.
In both study cohorts antibacterials for systemic use were the drugs
most often associated with ADRs [1999 cohort: n = 24 (11.9% of
all prescriptions for antibacterials); 2008 cohort: n = 20 (6.9% of all
prescriptions for antibacterials)], followed by corticosteroids for
systemic use [1999 cohort: n = 9 (33.3% of all prescriptions for
corticosteroids), 2008 cohort: n = 15 (27.8% of all prescriptions for
corticosteroids), respectively]. (Table 4)
In 2008 the majority of ADRs was classified as mild (n = 48,
90.6%). In contrast in 1999 54.3% (n= 25) of ADRs were found to
be mild and 41.3% (n= 19) were considered as moderate,
respectively. Only one ADR (from 2008 cohort) was found to be
severe.
Physicians’ awareness
The percentage of ADRs being recognized by the treating
physician was 45.7% in the 1999 cohort and rose to 96.2% in the
2008 cohort (p,0.001).
Regression
In both studies univariable analysis showed a significant
relationship between the number of high risk drugs and the
occurrence of ADRs. In the 1999 cohort we additionally found a
significant association between the number of low risk drugs and
the occurrence of ADRs and between diagnoses of ICD-Class ‘‘Q’’
and the occurrence of ADRs. In the 2008 cohort there was also a
significant association for the number of diagnoses per patient as
well as for diagnoses of ICD-Class ‘‘D’’. (Table 5)
In the multivariable regression analysis the association between the
number of high risk drugs (n.3) and the occurrence of ADRs only
remained significant in the 1999 cohort (OR 12.8; 95% CI, 1.1–
148.8). In the 2008 cohort this association became slightly insignif-
icant, although the OR still indicates that children with .3 high risk
drugs have a higher risk for ADRs (OR: 5.4, 95% CI, 0.9–33.8).
Diagnosis with a ‘‘D’’-code also remained significant in the 2008
cohort, however, this diagnosis was not reported in 1999. (Table 6)
There was no significant association between the length of
hospital stay and the occurrence of ADRs in the univariable
analysis in both studies. In the model of the 2008 cohort the OR
for a length of stay .7 days was lower compared to the model of
the 1999 cohort (2.3 vs. 5.6, respectively). However, there was no
significant association with ADRs occurrence, but a lot of
interactions with other factors.
Table 1. Comparison of patients’ characteristics from two study cohorts.{
Patients characteristics 1999 Cohort{ 95% CI 2008 Cohort{ 95% CI p-value*
Number of patients (admissions) 144 (167) - 376 (407) - -
Number of patients by age
groups, No. (%):
0–#2 years 68 (47.2%) 38.6–55.6 133 (35.4%) 30.5–40.4 p,0.05
Number of patients by age
groups, No. (%):
.2–#11 years 50 (34.7%) 27.0–43.1 156 (41.5%) 36.5–46.7 p,0.05
.11–#18 years 26 (18.1%) 12.1–25.3 87 (23.1%) 19.0–27.7 p,0.05
Age, years: median (IQR){{ 3.0 (1–8.5) 2.0–4.0 5.0 (1–10.5) 4.0–6.0 -
Gender, No. (%): female* 65 (45.8%)1 37.4–54.3 164 (43.6%) 38.5–48.8 p.0.05
male* 77 (54.2%)1 45.7–62.6 212 (56.4%) 51.2–61.5 p.0.05
Length of stay, days: median (IQR){{ 5 (2–10) 4.0–6.0 4 (3–6) 3.0–4.0 p,0.001
Diagnosis, no.: median (IQR){{ 1.0 (1–2) 1.0–2.0 2.0 (1–3) 2.0–2.0 p,0.001
Number of patients received medication (%) 128 (88.9%) 82.6–93.5 293 (77.9%) 73.4–82.0 p,0.001
Total number of drugs prescribed 710 - 1343 - -
Number of drugs prescribed per
patient in groups, No. (%):
no prescription 16 (11.1%) 6.5–17.4 83 (22.1%) 18.0–26.6 p,0.001
1–,5 prescriptions 78 (54.2%) 45.7–62.5 212 (56.4%) 51.2–61.5 p,0.001
5–10 prescriptions 48 (33.3%) 25.7–41.7 64 (17.0%) 13.4–21.2 p,0.001
.10 prescriptions 2 (1.4%) 0.2–4.9 17 (4.5%) 2.7–7.1 p,0.001
Number of drugs prescribed per patient: median (IQR){{ 3.0 (1.5–6) 2.0–4.0 2.0 (1–4) 2.0–3.0 p,0.01
Number of drugs prescribed per patient (only those with
medication): median (IQR){{
3.0 (2–6) 3.0–4.0 3.0 (2–5) 3.0–3.0 p,0.05
Number of patients with high risk drugs (%) 108 (75%/84.4%*) 67.1–81.8 76.9–90.2 234 (62.2%/
79.8%*)
57.1–67.2
74.8–84.3
p,0.01
p.0.05
*Chi-Squared test;
1two missings,
{{IQR = interquartile range.
doi:10.1371/journal.pone.0044349.t001
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Discussion
We present the results of two studies which were conducted
almost ten years apart using a similar methodology. We found an
overall ADR incidence of 13.1% (95% CI, 9.8–16.3) which is
slightly above the findings published previously [5,6,8,12].
However, it is still lower than the overall incidence observed in
our large international multi-centre study [15].
Our main finding is that there was a significant decrease of
ADR incidence between 1999 and 2008. There are various
reasons which may have led to this result.
Figure 1. Main classes of diagnosis based on ICD10 for the two study cohorts.
doi:10.1371/journal.pone.0044349.g001
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Polypharmacy
Polypharmacy has been associated with increased ADR
incidences and has previously been shown to be a risk factor
[12,27,32]. In our study the median number of drugs decreased
from three in 1999 to two in 2008 in the overall population but did
not change amongst those patients receiving at least one
medication. Thus the decrease in ADR incidence cannot be
explained by a decreasing use of medicines in general.
However, the multivariable regression analysis revealed that the
number of high risk drugs is the only independent risk factor for
the development of an ADR.
We determined that in the group of patients receiving
medication the percentage of patients receiving at least one
high risk drug decreased from 84.4% in 1999 to 79.8% in 2008.
In addition high risk drugs such as antibacterials for systemic
use were prescribed less often (28.4% to 21.7% of all
prescriptions) and the exposure rate, i.e. the percentage of
patients receiving at least one systemic antibacterial, decreased
from 82.0% in 1999 to 59.9% in 2008, respectively. Altogether,
this may explain the significantly decreasing ADR incidence
over time in our study.
Change of treatment strategies
Furthermore pharmacological treatment strategies on the ward
have changed during the nine years and therefore probably
influenced the incidence of ADRs.
For example more and different types of analgesics and anti-
inflammatory drugs were prescribed during the 2008 cohort, e.g.
we observed an increasing number of prescriptions for ibuprofen.
Ibuprofen became more popular in recent years since some studies
have proven the superior efficacy of ibuprofen compared to
paracetamol, when treating fever in children [33,34]. Increasing
use of ibuprofen was reported previously from other countries such
as the UK and Italy [35–37].
Furthermore, metamizol and paracetamol were also prescribed
more often in 2008 than in 1999. However, they were not
significantly associated with ADRs which confirms that both – and
particularly paracetamol – are long-established drugs which are
well studied in children and safe and effective when used
appropriately.
The increasing use of metamizol is an interesting development.
Some years ago metamizol was withdrawn from the market in
some countries or became a prescription only medicine in others
because of the risk of agranulocytosis. However, this adverse
reaction is very rare. On the other side metamizol has good
Figure 2. Most common prescribed drug classes in each study by ATC-T Level.
doi:10.1371/journal.pone.0044349.g002
ADRs Children Germany
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antipyretic and analgesic properties and can be administered
intravenously which allows a fast pain and fever relief. [38].
Therefore in some countries such as Germany it is well accepted
and commonly used in both children and adults.
Overall this development shows that the need for an adequate
treatment of pain and fever in children has been realised and is
currently put into practice in our hospital.
A similar picture as for analgesics was seen for systemic
antibacterials. The proportion of drugs involved in ADRs
compared to the total number of prescriptions in this group
declined from 11.9% to 6.9%. Drugs which often caused ADRs in
1999 such as imipenem, vancomycin and streptomycin were
prescribed less often in 2008.
This change may reflect the decreasing number of cystic fibrosis
patients treated on the study ward because treatment strategies
changed and their care – including treatment with parenteral
antibiotics – was moved from hospital to ambulant settings [39–
41].
Length of hospitalisation
As anticipated with the introduction of DRGs [16,17,42] the
length of hospitalisation significantly decreased between 1999 and
2008. Particularly the number of patients staying longer than 7
days in hospital decreased from 34% to 15.2%, respectively.
However, the univariable regression analysis showed no
significant association between length of hospitalisation (LOS)
Table 2. Exposure rates for most common antibacterials for systemic use and analgesics and anti-inflammatory drugs in two study
cohorts.{
1999 Cohort{ 2008 Cohort{
no patients
exposed
% all patients
(n =167)
% patients
receiving
medication
(n=128)
no patients
exposed
% all patients
(n =407)
% patients
receiving
medication
(n=293)
Antibacterials for systemic use (J01/J02) 105 62.9 82.0 173 42.5 59.0
b-Lactam, penicillins (J01C) 33 19.8 25.8 61 15.0 20.8
Other b-Lactam antibiotics (cephalophorins,
carbapenems) (J01D)
67 40.1 52.3 114 28.0 38.9
Macrolids, lincosamids and streptogramins (J01F) 19 11.4 14.8 19 4.7 6.5
Sulfonamids and trimethoprim (J01E) 16 9.6 12.5 17 4.2 5.8
Antimycotics for systemic use (J02A-V) 6 3.6 4.7 3 0.7 1.0
Aminoglycosids (J01G) 22 13.2 17.2 23 5.7 7.8
Analgesics (N02) 18 10.8 14.1 155 38.1 52.9
Paracetamol (N02BE0) 13 7.8 10.2 100 24.6 34.1
Metamizole (N02BB0) 6 3.6 4.7 115 28.3 39.2
Acetylsalicylic acid (N02BA01) 3 1.8 2.3 0.0 0.0
Tramadol (N02AX0) 0 0 0.0 6 1.5 2.0
Tilidine (N02AX0) 0 0 0.0 1 0.2 0.3
Buprenorphine (N02AE0) 0 0.0 0.0 1 0.2 0.3
Piritramide (N02AC0) 0 0.0 0.0 2 0.5 0.7
Anti-inflammatory drugs (M01) 12 7.2 9.4 119 29.2 40.6
Ibuprofen (M01AE0) 7 4.2 5.5 119 29.2 40.6
Indometacin (M01AB0) 5 3.0 3.9 0 0.0 0.0
Analgesics and anti-inflammatory drugs 29 17.4 22.7 184 45.2 62.8
doi:10.1371/journal.pone.0044349.t002
Table 3. Frequency of adverse drug reactions (ADR).
1999 Cohort % (95%-CI) 2008 Cohort % (95%-CI) p-value Overall % (95%-CI)
ADR proportion n= 28/144, 19.4 (13.0–26.0) n = 27/376, 7.2 (4.6–9.8) ,0.001 n= 55/520, 10.6 (7.9–13.2)
ADR incidence n= 28/128, 21.9 (14.7–29.0) n = 27/293, 9.2 (5.9–12.5) ,0.001 n= 55/421, 13.1 (9.8–16.3)
No of ADR/100 admissions 27.5 (20.7–34.3) 13.0 (9.9–16.7) ,0.001 17.2 (14.2–20.6)
No of ADR/100 days in hospital 4.4 (3.2–5.6) 2.6 (2.0–3.4) 0.09 3.6 (2.5–3.7)
Proportion of patients with an ADR as
reason for admission
0.0 n = 3/376, 0.8 (0.2–2.3) NA* n = 3/520, 0.6 (0.1–1.7)
*NA= not applicable.
doi:10.1371/journal.pone.0044349.t003
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and ADR occurrence in both studies. In the multivariable analysis,
the OR to have an ADR for patients staying ‘.7 days’ was higher
in the 1999 cohort as compared to the 2008 cohort but there was
still no significant association with ADRs occurrence in both
cohorts. This result is most likely to be explained by interactions
that have occurred with other factors such as the number of drugs
prescribed. Overall, the decrease in ADR incidence cannot be
explained by the decrease of LOS but rather with changes in
treatment strategies.
Nevertheless, as some ADRs take time to develop, they may
have been missed in the 2008 cohort as the patient – because of
the shorter LOS – was already discharged at the time the ADR
occurred. Therefore further research into ADRs in the ambulatory
care sector is needed to establish whether this is the case or not. So
far the real impact of the introduction of DRGs on the incidence
of ADRs remains unclear.
Study population
Although both studies were conducted on the same ward and
the dedication of the ward as predominantly infectious ward did
not change, some differences in the study population were
observed which may also have contributed to the decrease of
ADR frequency. In 1999 more younger children (0–,2 years)
were treated (47.2% vs. 35.4% of study population). One can
argue that younger children are more vulnerable and thus more
prone to developing adverse reaction to medications which could
have contributed to the lower ADR incidence in 2008. However,
in a previous large epidemiological study on ADR risk-factors we
could not identify age as independent risk factor towards ADRs
[15]. Similarly an extensive systematic review on ADRs in children
did also not identify a significant relationship between younger age
and the occurrence of ADRs. (p = 0.21) [11]
Despite the fact that infectious and parasitic diseases and
respiratory infections were most frequent, the percentage of
patients presenting with one of the above diagnoses within the
study cohort was lower in 2008 as compared to 1999. Congenital
malformations, deformations and chromosomal abnormalities
were less frequent in 2008 as compared to 1999. On the other
hand, in 2008 more endocrine, nutritional and metabolic disease
were treated on the ward as compared to 1999.
Thus, it appears that patients in the 1999 cohort had more
chronic and severe illnesses and thus needed more and stronger
medication. This change is mainly related to the fact that fewer
patients with cystic fibrosis were treated on the study ward because
of a change in their treatment strategies. (See also study strengths
and limitations).
Physician’s awareness
A strong increase in the detection of ADRs by treating
physicians, (45.7% in 1999 and 96.2% in 2008 respectively) was
identified. This implies that the awareness of healthcare profes-
sionals towards ADRs has been increased. Although the detection
rate documented in 2008 (96.2%) might be slightly overestimated
there was a significant increase in the physicians’ attention to
ADRs (p,0.001), which shows a positive development of ward
staffs’ alertness towards ADRs. A wide range of detection rates,
between 42.5% in Neubert et al (2006), 89% in Aagaard et al
(2010) and 91.1% in Haffner et al (2005) is reported in literature
[4,7,43].
Table 4. ADR causative drugs and examples of ADRs for each study by ATC-T-level categories.{
Drug groups (ATC)
ADR causative drugs (n)/total drugs in group
(n) (%)# Examples of ADRs (causative drug)
1999 Cohort, Total
n=710
2008 Cohort, Total
n =1343 1999 Cohort 2008 Cohort
analgesics* (N02) N= 0/23 (0.0%),
95%CI NA
N=2/225 (0.9%), 95%CI
(0.1–3.2)
- thrombocytopenia (metamizol),
sedation aggravated (tramadol)
antibacterials for systemic use* (J01/
J02)
N= 24/201 (11.9%),
95%CI (7.8–17.2)
N = 20/291 (6.9%), 95%CI
(4.2–10.4)
diarrhea (amoxicillin, imipenem),
exanthema (amoxicillin, vancomycin),
eosinophilia (cefaclor, cefotiam)
eosinophilia (vancomycin,
cefotaxim, tobramycin),
exanthema (amoxicillin,
benzylpenicillin), neutropenia
(cefotaxim)
antiepileptics* (N03) N= 1/22 (4.5%), 95%CI
(0.1–2.3)
N = 8/53 (15.1%), 95%CI
(6.7–27.6)
elevated liver enzymes (phenobarbital) thrombocytopenia (valproic
acid), leucopenia (valproic acid,
topiramate)
anti-inflammatory and antirheumatic
products (M01)
N= 3/12 (25%), 95%CI
(5.5–5.7)
N = 0/119 (0.0%), 95%CI
NA
nausea & vomiting (indometacin), GI-
bleeding (ibuprofen)
-
immuno-suppressive agents* (L04) N= 3/15 (20%), 95%CI
(4.3–4.8)
N = 8/36 (22.2%), 95%CI
(10.1–39.2)
diarrhea & hypertrichosis (ciclosporin),
herpes zoster (azathioprine)
hyponatriaemia & hyperkaliaemia
(tacrolimus), hypertrichosis
(ciclosporin)
corticosteroid for systemic use* (H02) N= 9/27 (33.3%), 95%CI
(16.5–54.0)
N = 15/54 (27.8%), 95%CI
(16.5–41.6)
hypokaliaemia (methylprednisolone),
leucocytosis (methylprednisolone)
hyperglycaemia, hypertension,
Cushing’s syndrome
(prednisone), leucocytosis
(prednisolone),
drugs for obstructive airway diseases
(R03)
N= 2/77 (2.6%), 95%CI
(0.3–9.1)
N = 0/60 (0.0%), 95%CI
NA{{
eosinophilia (theophylline), tachycardia
(epinephrine)
-
Drugs marked with (*) are high risk drugs;
#percentage of total prescriptions in this group causing an ADR.
{most often prescribed drugs (n.25),
{{NA=not applicable as it is one-sided, 97.5% CI.
doi:10.1371/journal.pone.0044349.t004
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Type and severity of ADRs
The proportion and incidence of ADRs decreased over the nine
year period. Additionally, in 2008 the proportion of ADRs being
moderate or severe was lower compared to 1999. However, this
finding may, in part, be due to subjectivity of the assessment scale
and differences in the two research groups.
In a previous multi-center study the inter-rater analysis of the
severity assessment was moderate (k = 0.55) which indicated that
there is some subjectivity in the severity assessment scale use [15].
Therefore interpretation of this finding needs to be cautious.
Differences in the pattern of ADRs might be, in part, linked to
the differences in drug usage, which in turn may have led to
different types of ADRs reported. For example, ADRs concerning
white cells and reticulo-endothelial system were reported in 2008
cohort, while in the 1999 cohort gastrointestinal and cutaneous
ADRs were the most frequent. The latter are frequently associated
with antibiotic use which was less common in the 2008 cohort
[12,30].
Study strengths and limitations
To our knowledge this is the first study to compare results of two
prospective observational cohort studies conducted in one large
academic children hospital in Germany at two time points. Both
studies used intensive chart review to detect ADRs. This method is
established as the gold standard for ADR detection [14,21].
For data from the ADVISE study this method was assessed by
re-evaluating 10 randomly selected patients by a second reviewer.
The inter-rater agreement for identifying patients with ADRs was
found to be ‘‘almost-perfect’’ with k = 0.89 (95%CI, 0.75–1.0),
which confirms the validity of the method used in this study [15].
However, there are also several limitations for this analysis.
Because of an increase in the number of beds on the study ward
between 1999 and 2008 the total number of patients included in
the 2008 cohort was higher than in 1999 (376 vs. 144). Therefore
the 1999 cohort is statistically less powerful.
In addition there was a transition of patients treated on the
ward. For instance fewer patients with cystic fibrosis were treated
because of switching parenteral antibiotic treatment from hospital
to home parenteral therapy. Furthermore patients with concussion
were admitted who did not receive any medication. However, we
accounted for these patients in our results as we also ran the
analysis for patients receiving at least one medication. The
decrease in ADR incidence was similar; hence the decreasing
number of patients receiving a medication was not the reason for
the declining ADR incidence.
In 1999 the documentation and analysis of data relied on hand-
written comments and manual transfer from the patients charts
only. For the purpose of this study, standardized ICD10- and
ATC-Codes had to be added manually. In 2008 the diagnosis and
drugs were electronically transferred to the database, which may
have provided a more complete picture. Nevertheless, the ADR
Table 5. Risk factors for ADRs in the two study cohorts (results of the univariable regression analysis).{
1999 Cohort{ 2008 Cohort{
OR (95%CI) p-value OR (95%CI) p-value
Age
0–#2 years 1.4 (0.5–3.6) 0.508 0.7 (0.2–2.0) 0.501
2–#11 years 1.0 (reference) 1.0 (reference)
.11–18 years 1.1 (0.3–3.7) 0.924 2.3 (0.9–5.8) 0.071
Gender (female vs. male) 1.3 (0.5–2.9) 0.569 0.8 (0.3–1.7) 0.512
Number of diagnoses per patient 1.3 (1.0–1.7) 0.076 1.3 (1.1–1.5)* ,0.01
Length of hospital stay .7days 7.9 (0.9–65.5) 0.057 0.9 (0.1–9.7) 0.951
Number of low risk drugs prescribed
0 1.0 (reference) 1.0 (reference)
,5 3.5 (0.4–28.7) 0.236 1.0 (0.3–3.1) 0.996
5–10 11.5 (1.3–102.7)* 0.028 2.1 (0.5–9.1) 0.327
.10 NA{{ 7.7 (1.0–60.2) 0.053
Number of high risk drug prescribed
0 1.0 (reference) 1.0 (reference)
1 1.5 (0.1–15.8) 0.716 0.8 (0.1–5.6) 0.797
2–3 8.3 (1.0–67.0)* 0.047 2.8 (0.6–13.3) 0.190
.3 26.6 (2.6–269.4)* ,0.01 10.9 (2.3–51.2)* ,0.01
Special ICD10 diagnosis groups
Diagnosis with code ‘‘D’’** NA{{ 11.4 (2.7–48.6)* ,0.01
Diagnosis with code ‘‘J’’*** 0.2 (0.1–1.0) 0.057 NA{{
Diagnosis with code ‘‘Q’’**** 4.1 (1.1–15.5)* 0.035 NA{{
*statistically significant variables (p,0.05);
**D =Diseases of the blood, the blood-forming organs and certain immune deficiencies;
***J = Respiratory diseases;
****Q=Congenital malformations, deformations and chromosomal abnormalities.
{{NA=Not applicable.
doi:10.1371/journal.pone.0044349.t005
ADRs Children Germany
PLOS ONE | www.plosone.org 9 September 2012 | Volume 7 | Issue 9 | e44349
incidence decreased although more information had been
available.
Conclusion
Over a 9-year period the incidence of ADRs decreased
significantly on a general paediatric ward. Clinicians were also
shown to be more aware of ADRs. Overall less medication is used
and a clear change in the prescribing behaviour has been noticed.
However it remains unclear to which extent there was a shift of the
problem into primary care because of a decreasing length of
hospital stay. Therefore further research on ADRs in primary care
is needed.
Overall, the need for pharmacovigilance in the paediatric
population, at least in our hospital has been realised. The next step
will now be to establish prospective pharmacovigilance systems to
improve medication safety in paediatrics.
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